These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30410159)

  • 21. Extrapyramidal Symptoms as a Result of Risperidone Discontinuation During Combination Therapy with Methylphenidate in a Pediatric Patient.
    Pérez CA; Garcia SS; Yu RD
    J Child Adolesc Psychopharmacol; 2016 Mar; 26(2):182. PubMed ID: 26871198
    [No Abstract]   [Full Text] [Related]  

  • 22. A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition.
    Malla A; Norman R; Scholten D; Townsend L; Manchanda R; Takhar J; Haricharan R
    Psychiatry Res; 2004 Dec; 129(2):159-69. PubMed ID: 15590043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
    Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
    Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risperidone for the treatment of behavioral and psychological symptoms of dementia.
    Tune LE
    J Clin Psychiatry; 2001; 62 Suppl 21():29-32. PubMed ID: 11584986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome: A Prospective Longitudinal Study.
    Pringsheim T; Ho J; Sarna JR; Hammer T; Patten S
    J Clin Psychopharmacol; 2017 Oct; 37(5):498-504. PubMed ID: 28816926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety.
    Davies A; Adena MA; Keks NA; Catts SV; Lambert T; Schweitzer I
    Clin Ther; 1998; 20(1):58-71. PubMed ID: 9522104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway.
    Mas S; Gassó P; Ritter MA; Malagelada C; Bernardo M; Lafuente A
    Eur Neuropsychopharmacol; 2015 Jan; 25(1):51-9. PubMed ID: 25499605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clozapine-related extrapyramidal side effects: a case report.
    Gallo M; Squarcione C; Bersani FS; Minichino A; Fojanesi M; Biondi M
    Riv Psichiatr; 2017; 52(4):172-173. PubMed ID: 28845867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.
    Gassó P; Mas S; Bernardo M; Alvarez S; Parellada E; Lafuente A
    Pharmacogenomics J; 2009 Dec; 9(6):404-10. PubMed ID: 19506579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone.
    Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Honer WG
    Am J Psychiatry; 2001 Apr; 158(4):625-31. PubMed ID: 11282699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Movement disorders associated with neuroleptic treatment.
    Wirshing WC
    J Clin Psychiatry; 2001; 62 Suppl 21():15-8. PubMed ID: 11584982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
    Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
    Ann Pharmacother; 2001 Dec; 35(12):1517-22. PubMed ID: 11793611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
    Zalsman G; Carmon E; Martin A; Bensason D; Weizman A; Tyano S
    J Child Adolesc Psychopharmacol; 2003; 13(3):319-27. PubMed ID: 14642020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.
    Nishimura K; Tsuka M; Horikawa N
    Eur Neuropsychopharmacol; 2001 Aug; 11(4):323-4. PubMed ID: 11532387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risperidone treatment of behavioral disturbances in outpatients with dementia.
    Irizarry MC; Ghaemi SN; Lee-Cherry ER; Gomez-Isla T; Binetti G; Hyman BT; Growdon JH
    J Neuropsychiatry Clin Neurosci; 1999; 11(3):336-42. PubMed ID: 10440009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective prescribing of atypical antipsychotics.
    Breekveldt-Postma NS; Schillevoort I; Nolen WA; Veraart CP; Herings RM
    Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):25-30. PubMed ID: 15508132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comment: risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
    Lu ML; Shen WW
    Ann Pharmacother; 2002; 36(7-8):1292; author reply 1292-3. PubMed ID: 12086567
    [No Abstract]   [Full Text] [Related]  

  • 39. Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications.
    Carter CS; Mulsant BH; Sweet RA; Maxwell RA; Coley K; Ganguli R; Branch R
    Psychopharmacol Bull; 1995; 31(4):719-25. PubMed ID: 8851645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extrapyramidal side effects in a patient treated with risperidone plus donepezil.
    Magnuson TM; Keller BK; Burke WJ
    Am J Psychiatry; 1998 Oct; 155(10):1458-9. PubMed ID: 9766783
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.